Evogene (EVGN) Cash from Operations (2013 - 2026)
Evogene (EVGN) posted Cash from Operations of 2954000.0 for Q1 2026, down 9.98% sequentially from 2686000.0 in Q4 2025, and up 42.99% YoY from 2065806.75 in Q1 2025.
Evogene (EVGN) Cash from Operations (2013 - 2026) Analysis & Trends
Evogene has reported Cash from Operations for 14 years, with the latest figure at 2954000.0 in Q1 2026.
- Quarterly Cash from Operations rose 42.99% year-over-year to 2954000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13123000.0 (down 42.39% YoY) and the FY2025 annual result came in at 13502000.0, up 31.46% from the prior year.
- Cash from Operations retreated to 2954000.0 in Q1 2026 per EVGN's latest filing, from 2686000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 7707000.0 in Q1 2022 and troughed at 7056000.0 in Q3 2022.
- A 5-year average of 1159375.0 and a median of 2820000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations soared 362.52% in 2023, then slumped 226.08% in 2025.
- Over 5 years, Cash from Operations stood at 2257000.0 in 2022, then surged by 362.52% to 5925000.0 in 2023, then plunged by 176.98% to 4561000.0 in 2024, then soared by 41.11% to 2686000.0 in 2025, then declined by 9.98% to 2954000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2954000.0, 2686000.0, and 2301000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.95 Mn |
| Mar 31, 2026 | -2.95 Mn |
| Dec 31, 2025 | -2.69 Mn |
| Dec 31, 2025 | -2.69 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Mar 31, 2025 | -5.18 Mn |
| Mar 31, 2025 | -5.18 Mn |
| Dec 31, 2024 | -4.56 Mn |
| Dec 31, 2024 | -4.56 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Jun 30, 2024 | 5.46 Mn |
| Jun 30, 2024 | 5.46 Mn |
| Mar 31, 2024 | 4.11 Mn |
| Mar 31, 2024 | 4.11 Mn |
| Dec 31, 2023 | 5.93 Mn |
| Dec 31, 2023 | 5.93 Mn |
| Sep 30, 2023 | -4.32 Mn |
| Sep 30, 2023 | -4.32 Mn |